Literature DB >> 26002890

Acoustic Dispensing Preserves the Potency of Therapeutic Peptides throughout the Entire Drug Discovery Workflow.

Jacqueline Naylor1, Alessandra Rossi1, David C Hornigold2.   

Abstract

Routine peptide structure-activity relationship screening requires the serial dilution of peptides to produce full concentration-response curves. Established tip-based protocols involve multiple tip changes and high exposure to plasticware. In the case of peptides, this becomes a challenge, since peptides can adsorb to plastic, resulting in an observed loss of potency. Various methods can be employed to prevent peptide loss during compound handling, such as the inclusion of bovine serum albumin or solvents in assay buffer and the siliconization of plasticware, yet protein binding remains unpredictable. The degree of variation by which peptides will adhere to plasticware can confuse results and cause inaccuracies in potency predictions. We evaluated acoustic noncontact methods for peptide serial dilution and compared it with traditional tip-based methods, on the effect on potency curves for glucagon-like peptide-1 and glucagon peptide analogues. The current study demonstrates the benefits of noncontact dispensing for high-density microplate assay preparation of peptides using nanoliter droplets across our entire drug discovery workflow, from in vitro high-throughput screening to drug exposure determinations from in vivo samples.
© 2015 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  EC50; GLP-1; acoustic droplet ejection; cAMP; glucagon

Mesh:

Substances:

Year:  2015        PMID: 26002890     DOI: 10.1177/2211068215587915

Source DB:  PubMed          Journal:  J Lab Autom        ISSN: 2211-0682


  6 in total

1.  Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays.

Authors:  Jacqueline Naylor; Alessandra Rossi; Christopher Brankin; David C Hornigold
Journal:  J Vis Exp       Date:  2016-11-10       Impact factor: 1.355

2.  Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly.

Authors:  Myriam M Ouberai; Ana L Gomes Dos Santos; Sonja Kinna; Shimona Madalli; David C Hornigold; David Baker; Jacqueline Naylor; Laura Sheldrake; Dominic J Corkill; John Hood; Paolo Vicini; Shahid Uddin; Steven Bishop; Paul G Varley; Mark E Welland
Journal:  Nat Commun       Date:  2017-10-18       Impact factor: 14.919

3.  A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice.

Authors:  David C Hornigold; Emma Roth; Victor Howard; Sarah Will; Stephanie Oldham; Matthew P Coghlan; Clemence Blouet; James L Trevaskis
Journal:  Appetite       Date:  2018-05-19       Impact factor: 3.868

4.  Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy.

Authors:  M Pilar Valdecantos; Laura Ruiz; Virginia Pardo; Luis Castro-Sanchez; Carmelo García-Monzón; Borja Lanzón; Javier Rupérez; Coral Barbas; Jaqueline Naylor; James L Trevaskis; Joseph Grimsby; Cristina M Rondinone; Ángela M Valverde
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

5.  An efficient system for bioconjugation based on a widely applicable engineered O-glycosylation tag.

Authors:  Thomas V Murray; Kasia Kozakowska-McDonnell; Adam Tibbles; Annabel Taylor; Daniel Higazi; Emmanuel Rossy; Alessandra Rossi; Sivaneswary Genapathy; Giulia Tamburrino; Nicola Rath; Natalie Tigue; Vivian Lindo; Tristan Vaughan; Monika A Papworth
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

6.  Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.

Authors:  S J Henderson; A Konkar; D C Hornigold; J L Trevaskis; R Jackson; M Fritsch Fredin; R Jansson-Löfmark; J Naylor; A Rossi; M A Bednarek; N Bhagroo; H Salari; S Will; S Oldham; G Hansen; M Feigh; T Klein; J Grimsby; S Maguire; L Jermutus; C M Rondinone; M P Coghlan
Journal:  Diabetes Obes Metab       Date:  2016-08-15       Impact factor: 6.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.